BCOTP Solid Organ Transplant Pharmacy Certification Exam 2026:
Comprehensive Board Practice Test — Transplant Pharmacotherapy,
Immunosuppression, Rejection Management, Opportunistic
Infections, Drug Interactions & Therapeutic Monitoring — Multiple-
Choice Questions with Answers & Detailed Rationales
Section 1: Transplant Biology, Immunology, and Organ Allocation (Questions 1–12)
Question 1
A 34-year-old male with end-stage renal disease secondary to IgA nephropathy is being
evaluated for deceased donor kidney transplantation. His calculated panel reactive antibody
(cPRA) is 98%. Which of the following immunologic barriers poses the greatest challenge to
finding a compatible organ offer for this patient?
A. Pre-formed IgM antibodies against ABO blood group antigens
B. High titer IgG donor-specific antibodies against HLA class I and II antigens
C. Natural killer cell-mediated cytotoxicity against donor endothelial cells
D. Regulatory T-cell deficiency leading to impaired self-tolerance
Correct Answer: B
Explanation: A cPRA of 98% indicates the presence of broad HLA sensitization. Pre-formed
IgG donor-specific antibodies (DSAs) against class I and II HLA antigens create the primary
immunologic barrier, leading to positive crossmatches and increased risk of hyperacute and
antibody-mediated rejection .
Question 2
A 58-year-old female with hepatitis C virus (HCV)-related cirrhosis is listed for liver
transplantation. The transplant team is considering using a donor organ from an HCV-
positive donor. Which of the following statements reflects current best practice regarding
HCV-positive donors in the era of direct-acting antiviral (DAA) therapy?
,A. HCV-positive donors remain an absolute contraindication for all liver transplant
candidates.
B. HCV-positive donors may be considered for HCV-negative recipients with the plan for post-
transplant DAA therapy if viral transmission occurs.
C. HCV-positive donors may only be used for recipients who are already HCV RNA positive at
the time of transplant.
D. HCV-positive donor organs are associated with inferior graft survival despite DAA therapy
and should be avoided in all cases.
Correct Answer: B
Explanation: With highly effective DAAs, HCV-positive donor organs can be safely
transplanted into HCV-negative recipients, with post-transplant DAA therapy initiated if
transmission occurs (or preemptively). This strategy expands the donor pool significantly .
Question 3
Which of the following mechanisms best describes the primary pharmacodynamic action of
basiliximab, an IL-2 receptor antagonist used for induction immunosuppression in solid
organ transplantation?
A. Depletion of complement-fixing B cells through antibody-dependent cellular cytotoxicity
B. Inhibition of calcineurin phosphatase, blocking IL-2 gene transcription in T cells
C. Binding to the alpha chain (CD25) of the IL-2 receptor on activated T lymphocytes,
preventing IL-2-mediated proliferation
D. Blocking the co-stimulatory signal between CD28 on T cells and CD80/86 on antigen-
presenting cells
Correct Answer: C
,Explanation: Basiliximab is a chimeric monoclonal antibody directed against the alpha
subunit (CD25) of the IL-2 receptor. By blocking this receptor, it prevents IL-2 from driving
the clonal expansion of activated T lymphocytes .
Question 4
A 62-year-old male is scheduled to receive a heart transplant from a donor with a history of
hypertension and diabetes. The procurement team notes that the donor had documented
coronary artery disease on angiography. According to standard organ allocation criteria,
which of the following best describes the impact of this donor’s characteristics?
A. The donor heart is absolutely contraindicated due to the risk of transmitting coronary
artery disease.
B. The donor heart may be considered for a recipient with a low predicted post-transplant
survival benefit.
C. The donor heart is considered an expanded criteria donor (ECD) organ, requiring informed
consent regarding potential reduced graft survival.
D. The donor heart is acceptable only for a recipient who is willing to accept a higher risk of
primary graft dysfunction.
Correct Answer: C
Explanation: Hearts from donors with specific risk factors (e.g., age, hypertension, diabetes,
coronary disease) are often classified as expanded criteria donors. Use of these organs
requires informed consent and acceptance of potentially reduced graft survival compared to
standard criteria donors .
Question 5
In the context of transplant immunology, which of the following processes describes the
recognition of donor alloantigens directly by recipient T lymphocytes via intact MHC
molecules on the surface of donor antigen-presenting cells (passenger leukocytes)?
A. Indirect allorecognition
, B. Semi-direct allorecognition
C. Direct allorecognition
D. Cross-reactive allorecognition
Correct Answer: C
Explanation: Direct allorecognition occurs when recipient T cells recognize intact donor MHC
molecules present on the surface of donor APCs (passenger leukocytes) that have migrated
from the graft. This is a potent stimulus for early acute rejection .
Question 6
A 45-year-old female with end-stage lung disease due to cystic fibrosis is undergoing
transplant evaluation. The transplant pharmacist is asked to review her immunization
history. According to CDC and AST guidelines, which of the following vaccines is
contraindicated post-transplant but should be administered at least 4 weeks prior to
transplantation if indicated?
A. Inactivated influenza vaccine
B. Pneumococcal conjugate vaccine (PCV13)
C. Measles, mumps, and rubella (MMR) vaccine
D. Recombinant hepatitis B vaccine
Correct Answer: C
Explanation: Live attenuated vaccines such as MMR are contraindicated after transplantation
due to the risk of vaccine-strain infection in immunosuppressed patients. They should be
administered at least 4 weeks before planned immunosuppression when possible .
Question 7
Comprehensive Board Practice Test — Transplant Pharmacotherapy,
Immunosuppression, Rejection Management, Opportunistic
Infections, Drug Interactions & Therapeutic Monitoring — Multiple-
Choice Questions with Answers & Detailed Rationales
Section 1: Transplant Biology, Immunology, and Organ Allocation (Questions 1–12)
Question 1
A 34-year-old male with end-stage renal disease secondary to IgA nephropathy is being
evaluated for deceased donor kidney transplantation. His calculated panel reactive antibody
(cPRA) is 98%. Which of the following immunologic barriers poses the greatest challenge to
finding a compatible organ offer for this patient?
A. Pre-formed IgM antibodies against ABO blood group antigens
B. High titer IgG donor-specific antibodies against HLA class I and II antigens
C. Natural killer cell-mediated cytotoxicity against donor endothelial cells
D. Regulatory T-cell deficiency leading to impaired self-tolerance
Correct Answer: B
Explanation: A cPRA of 98% indicates the presence of broad HLA sensitization. Pre-formed
IgG donor-specific antibodies (DSAs) against class I and II HLA antigens create the primary
immunologic barrier, leading to positive crossmatches and increased risk of hyperacute and
antibody-mediated rejection .
Question 2
A 58-year-old female with hepatitis C virus (HCV)-related cirrhosis is listed for liver
transplantation. The transplant team is considering using a donor organ from an HCV-
positive donor. Which of the following statements reflects current best practice regarding
HCV-positive donors in the era of direct-acting antiviral (DAA) therapy?
,A. HCV-positive donors remain an absolute contraindication for all liver transplant
candidates.
B. HCV-positive donors may be considered for HCV-negative recipients with the plan for post-
transplant DAA therapy if viral transmission occurs.
C. HCV-positive donors may only be used for recipients who are already HCV RNA positive at
the time of transplant.
D. HCV-positive donor organs are associated with inferior graft survival despite DAA therapy
and should be avoided in all cases.
Correct Answer: B
Explanation: With highly effective DAAs, HCV-positive donor organs can be safely
transplanted into HCV-negative recipients, with post-transplant DAA therapy initiated if
transmission occurs (or preemptively). This strategy expands the donor pool significantly .
Question 3
Which of the following mechanisms best describes the primary pharmacodynamic action of
basiliximab, an IL-2 receptor antagonist used for induction immunosuppression in solid
organ transplantation?
A. Depletion of complement-fixing B cells through antibody-dependent cellular cytotoxicity
B. Inhibition of calcineurin phosphatase, blocking IL-2 gene transcription in T cells
C. Binding to the alpha chain (CD25) of the IL-2 receptor on activated T lymphocytes,
preventing IL-2-mediated proliferation
D. Blocking the co-stimulatory signal between CD28 on T cells and CD80/86 on antigen-
presenting cells
Correct Answer: C
,Explanation: Basiliximab is a chimeric monoclonal antibody directed against the alpha
subunit (CD25) of the IL-2 receptor. By blocking this receptor, it prevents IL-2 from driving
the clonal expansion of activated T lymphocytes .
Question 4
A 62-year-old male is scheduled to receive a heart transplant from a donor with a history of
hypertension and diabetes. The procurement team notes that the donor had documented
coronary artery disease on angiography. According to standard organ allocation criteria,
which of the following best describes the impact of this donor’s characteristics?
A. The donor heart is absolutely contraindicated due to the risk of transmitting coronary
artery disease.
B. The donor heart may be considered for a recipient with a low predicted post-transplant
survival benefit.
C. The donor heart is considered an expanded criteria donor (ECD) organ, requiring informed
consent regarding potential reduced graft survival.
D. The donor heart is acceptable only for a recipient who is willing to accept a higher risk of
primary graft dysfunction.
Correct Answer: C
Explanation: Hearts from donors with specific risk factors (e.g., age, hypertension, diabetes,
coronary disease) are often classified as expanded criteria donors. Use of these organs
requires informed consent and acceptance of potentially reduced graft survival compared to
standard criteria donors .
Question 5
In the context of transplant immunology, which of the following processes describes the
recognition of donor alloantigens directly by recipient T lymphocytes via intact MHC
molecules on the surface of donor antigen-presenting cells (passenger leukocytes)?
A. Indirect allorecognition
, B. Semi-direct allorecognition
C. Direct allorecognition
D. Cross-reactive allorecognition
Correct Answer: C
Explanation: Direct allorecognition occurs when recipient T cells recognize intact donor MHC
molecules present on the surface of donor APCs (passenger leukocytes) that have migrated
from the graft. This is a potent stimulus for early acute rejection .
Question 6
A 45-year-old female with end-stage lung disease due to cystic fibrosis is undergoing
transplant evaluation. The transplant pharmacist is asked to review her immunization
history. According to CDC and AST guidelines, which of the following vaccines is
contraindicated post-transplant but should be administered at least 4 weeks prior to
transplantation if indicated?
A. Inactivated influenza vaccine
B. Pneumococcal conjugate vaccine (PCV13)
C. Measles, mumps, and rubella (MMR) vaccine
D. Recombinant hepatitis B vaccine
Correct Answer: C
Explanation: Live attenuated vaccines such as MMR are contraindicated after transplantation
due to the risk of vaccine-strain infection in immunosuppressed patients. They should be
administered at least 4 weeks before planned immunosuppression when possible .
Question 7
